comparemela.com

Latest Breaking News On - மார்கஸ் போக்டன் - Page 1 : comparemela.com

Why CSL is still a buy | Money Management

Nevertheless, Australian equities manager Malcolm Whitten from Tyndall Asset Management and Marcus Bogdan from Blackmore Capital were optimistic on the business. “We think CSL is fair value, it was a safe haven in COVID-19 and a potential vaccine supplier. But on the re-opening, it underperformed, and that underperformance created opportunities to re-enter the stock,” said Whitten, who managed the Nikko AM Australian Shares Income fund. “While it was in lockdown, people were scared to go out and donate blood so the lack of blood availability constrained supply. But now the fading effects of the welfare payments in the US should mean supply increases; when there is high unemployment then blood donations increase.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.